Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Mavyret (glecaprevir and pibrentasvir)
Asia
No love for Merck, BMS PD-1s on China's reimbursement list
It’s a familiar scene in the race onto China’s national reimbursement list: Drugmakers cut prices by an average 60.7% to win coverage.
Angus Liu
Dec 2, 2019 11:59am
Gilead’s hep C generics now own more than 20% of market
Sep 16, 2019 11:34am
FDA flags liver risks for AbbVie, Merck, Gilead hep C meds
Aug 29, 2019 10:45am
Gilead airs first ads for hep C brand Epclusa
Feb 4, 2019 10:22am
AbbVie's latest hep C ads highlight Mavyret's time-to-cure edge
Dec 12, 2018 11:10am
Newcomers hit pharma's top TV spenders list for November
Dec 12, 2018 10:33am
